Código QR

Prognostic factors for patients treated with abiraterone

Aim: To evaluate prostate-specific antigen response (PSAr) defined as a ≥50% decrease in PSA concentration from the pretreatment value, as a prognostic factor in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA). Methods: Retrospective evalua...

Descrición completa

Gardado en:
Principais autores: Cecília M Alvim, André Mansinho, Rita S Paiva, Raquel Brás, Patrícia M Semedo, Soraia Lobo-Martins, Carolina B da Ponte, Daniela Macedo, Leonor Ribeiro, José P dos Reis, Isabel Fernandes, Luís Costa
Formato: Artigo
Idioma:Inglês
Publicado: Taylor & Francis Group 2020-02-01
Series:Future Science OA
Assuntos:
abiraterone acetate
metastatic castration-resistant prostate cancer
prostate-specific antigen response
Acceso en liña:https://www.future-science.com/doi/10.2144/fsoa-2019-0079
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares